A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 4 I, 1999, Pages

  Lumry, William R ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b American Board of Allergy and Immunology   (United States)

Author keywords

Allergic rhinitis; Intranasal steroids; Perennial rhinitis

Indexed keywords

BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; MOMETASONE FUROATE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MULTICENTER STUDY; PERENNIAL RHINITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033508816     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70311-8     Document Type: Article

References (44)

1. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneim Forsch Drug Res 1998;48:956-60.
2. Luzzani F, Gallico L, Glässer A. In vitro and ex vivo binding to uterine progestin receptors of the rat as a tool to assay progestational activity of glucocorticoids. Methods Find Exp Clin Pharmacol 1982;4:237-42.
3. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998;101(Suppl):S434-9.
4. Fokkens WJ, Godthelp T, Holm AF, Klein-Jan A. Local corticosteroid treatment: the effect on cells and cytokines in nasal allergic inflammation. Am J Rhinol 1998;12:21-6.
5. Meltzer EO. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy 1997;52(36 Suppl):33-40.
6. Fokkens WJ, Godthelp T, Holm AF, Blom H, Klein-Jan A. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Allergy 1997;52(36 Suppl):29-32.
7. Levenson T, Greenberger PA. Immunologic effects of intranasal corticosteroids. Allergy Asthma Proc 1996;17:157-9.
8. + T cells. J Allergy Clin Immunol 1997;100:511-9.
9. Barton BE, Jakway JP, Smith SR, Siegel MI. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol 1991;13:251-61.
10. Therattil J, Chavarria V, Cosachov J, Kumar N, Wang SF, Sansone G, et al. The effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis (SAR) [abstract P106]. Ann Allergy Asthma Immunol 1997;78:129.
11. Pipkorn U, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 1987;316:1506-10.
12. Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med 1995;151:1900-6.
13. Masuyama K, Jacobson MR, Rak S, Meng Q, Sudderich RM, Kay AB, et al. Topical glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994;82:192-9.
14. Ghaffar O, Laberge S, Jacobson MR, et al. IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: comparison with IL-4 expression and modulation by topical glucocorticoid therapy. Am J Respir Cell Mol Biol 1997;17:17-24.
15. Meltzer EO, Jalowayski AA, Orgel HA, Harris AG. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol 1998:102:39-49.
16. Wiseman LR, Benfield P. Intranasal fluticasone propionate: a reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs 1997;53:885-907.
17. Jeal W, Faulds D. Triamcinolone acetonide: a review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs 1997;53:257-80.
18. Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs 1992;44:375-407.
19. Physicians' desk reference. 52nd ed. Montvale (NJ): Medical Economics; 1998.
20. Berkowitz RB, Nolop KB, Mesarina-Wicki BE, C93-184 Study Group. Onset of action of mometasone furoate (Nasonex™) nasal spray in seasonal allergic rhinitis [abstract 1790]. J Allergy Clin Immunol 1997;99(Suppl):S441.
21. Derendorf H, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Sourgens H, et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995;35:302-5.
22. Berkowitz RB, Roberson S, Zora J, Harris A, Capano D, Chen R, et al. Onset of action of mometasone furoate nasal spray (MFNS) in seasonal allergic rhinitis (SAR) [abstract 1010]. J Allergy Clin Immunol 1998;101(Suppl):S244.
23. Chervinsky P. Clinical review of once-daily beclomethasone dipropionate for seasonal allergic rhinitis. Clin Ther 1996;18:790-6.
24. Davies RJ, Nelson HS. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther 1997;19:27-38.
25. Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex™) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 1996;51:569-76.
26. Graft D, Aaronson D, Chervinsky P, Kaiser H, Melamed J, Pedinoff A, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996;98:724-31.
27. Marazzi P, Nolop K, Lutsky BN, 193-133 Study Group. Prophylactic use of once-daily mometasone furoate (Nasonex™) aqueous nasal spray in patients with seasonal allergic rhinitis [abstract 1789]. J Allergy Clin Immunol 1997;99(Suppl):S440.
28. LaForce CF, Dockhorn RJ, Findlay SR, Meltzer EO, Nathan RA, Stricker W, et al. Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. J Fam Pract 1994;38:145-52.
29. Drouin M, Yang WH, Bertrand B, Van Cauwenberge P, Clement P, Dalby K, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996;77:153-60.
30. Day J, Nolop K, Lutsky BN, 194-079 Study Group. Comparison of once-daily treatment with mometasone furoate (Nasonex™) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis [abstract 1792]. J Allergy Clin Immunol 1997;99(Suppl):S441.
31. Brannan MD, Seiberling M, Cutler DL, Cuss FM, Affrime MB. Lack of systemic activity with intranasal mometasone furoate [abstract 62]. J Allergy Clin Immunol 1996;97(Suppl):198.
32. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997;19:1330-9.
33. Brannan MD, Herron JM, Reidenberg P, Affrime MB. Lack of HPA axis suppression following 36 days of intranasal mometasone furoate [abstract]. Ann Allergy Asthma Immunol 1997;78:154.
34. Wilson AM, McFarlane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal axis activity. J Allergy Clin Immunol 1998;101:470-4.
35. Foresi A, Pelucchi A, Cherson G, Mastropasqua B, Chiapparino A, Testi R. Once daily intranasal fluticasone propionate (200 mg) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996;98:274-82.
36. Knutsson U, Stierna P, Marcus C, Carlstedt-Duke J, Carlström K, Brönnegård M. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol 1995;144:301-10.
37. Pipkorn U, Pukander J, Suonpää J, Mäkinen J, Lindquist N. Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study. Clin Allergy 1988;18:253-9.
38. Minshall E, Ghaffar O, Cameron L, O'Brien F, Quinn H, Rowe-Jones J, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex™) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998;118:648-54.
39. Berg ØH, Lie K, Steinsvåg SK. The effects of topical nasal steroids on rat respiratory mucosa in vivo, with special reference to benzalkonium chloride. Allergy 1997;52:627-32.
40. Wolthers OD, Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr 1993;82:635-40.
41. Rachelefsky GS, Chervinsky P, Meltzer EO, Morris RM, Seltzer JM, Skoner DP, et al. An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray (Vancenase AQ [vns]) on long-term growth on children [abstract 979]. J Allergy Clin Immunol 1998;101:5236.
42. Möller C, Ek L, Svensson I-L. Nasal budesonide to children for 5 years [abstract 1546]. Allergy Clin Immunol News 1994;6(2 Suppl):427.
43. Schenkel EJ, Skoner DP, Bronsky EA. One-year of treatment with mometasone furoate aqueous nasal spray (MFNS) does not suppress growth in children [abstract]. Eur J Allergy Clin Immunol 1999;54(Suppl. 52) 0:74-5.
44. Allen DB. Influence of inhaled corticosteroids on growth: a pediatric endocrinologistes perspective. Acta Paediatr 1998;87:123-9.